UBS analyst Josh Silverstein raised the firm’s price target on Ovintiv to $47 from $46 and keeps a Buy rating on the shares. The firm sees Ovintiv’s update as a positive catalyst for the shares with the post-acquisition picture becoming clearer, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OVV:
- DraftKings upgraded, Coinbase downgraded: Wall Street’s top analyst calls
- Ovintiv reinstated with a Neutral at Goldman Sachs
- Ovintiv price target lowered to $39 from $42 at Evercore ISI
- Ovintiv price target raised to $39 from $36 at Wells Fargo
- Ovintiv closes Midland Basin asset sale, updates capital invesment view
